Company news
Ainos, Inc. (NASDAQ:AIMD) news
Ainos, Inc. news releases on 6ix. Latest, Jun 26, 2025: Ainos Aligns Capital Structure With 2H 2025 Execution Roadmap; Announces Stock Consolidation
Press releases — page 2
Ainos Aligns Capital Structure With 2H 2025 Execution Roadmap; Announces Stock Consolidation
June 26, 2025
Ainos and Kenmec Launch Strategic Partnership to Deploy AI-Powered Scent Intelligence in Smart Factories Across Asia
June 24, 2025
Ainos Issues Mid-Year Update: Reaching Strategic Inflection in SmellTech and Immunotherapy
June 16, 2025
Ainos AI Nose Improves Accuracy in Hygiene Monitoring To 85% from 80%
May 29, 2025
Ainos Showcases Breakthrough AI Nose Technology at COMPUTEX 2025 with Japan's Robotics Partner
May 22, 2025
AINOS (NASDAQ: AIMD) Signs Long-Form Interview and National TV Commercial Agreement with New to The Street
May 21, 2025
Ainos Reports Breakthrough Interim Results in VELDONA Clinical Trial for FCGS, Signaling New Era in Companion Animal Immunotherapy
May 19, 2025
Ainos Reports First Quarter 2025 Financial Results
May 12, 2025
Ainos Forms Partnership with ASE's Key Site to Power AI-Driven SmellTech in Semiconductor Smart Manufacturing
April 30, 2025
Ainos and ugo Complete First Robotic Smell Integration in Japan
April 21, 2025
Ainos Secures TFDA Approval and IRB Clearance to Advance VELDONA Clinical Trials for HIV Oral Warts and Sjogren's syndrome in Taiwan
April 15, 2025
Ainos Secures TFDA Approval and IRB Clearance to Advance VELDONA Clinical Trials for HIV Oral Warts and Sjögren's Syndrome in Taiwan
April 14, 2025
Ainos to Participate in Fireside Chat with Water Tower Research on April 8, 2025
March 24, 2025
Ainos and ASE Partner to Power AI Scent Digitization in Semiconductor Manufacturing
March 11, 2025
Ainos Reports Full Year 2024 Financial Results
March 7, 2025
Ainos and ugo to Develop the World's First Robot With a Sense of Smell
March 5, 2025
Ainos Achieves Major Breakthrough: Japan Patent Approval for VELDONA Redefines Antiviral Innovation
January 26, 2025
Ainos Unveils AI Nose for Robotics: Invites Global Robotics Companies to Join Forces in Shaping the Future of Smell-Enabled Robots
January 12, 2025
Ainos, Inc. Announces Strategic Partnership with Taiwan Tanabe Seiyaku to Advance Manufacturing and Taiwan Market Promotion of Sjögren's Syndrome Drug
December 1, 2024
Ainos Announces IRB Approval for Sjögren’s Syndrome Clinical Study at Shuang Ho Hospital, Affiliated with Taipei Medical University, and Plans to Initiate New Phase of Treatment Evaluation in Q1 2025
November 10, 2024
Ainos Reports Third Quarter 2024 Financial Results
November 5, 2024
Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA
September 24, 2024
Ainos Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjögren's Syndrome, a Rare Disease With Limited Treatment Options
September 22, 2024
Ainos Announced Plan to Initiate Taiwan Clinical Study for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA
September 16, 2024
Ainos Secures Exclusive Multi-Regions Invention Patent Licenses from Strategic Partner to Bolster AI Nose and Point-Of-Care Testing
August 8, 2024
Ainos Concludes Growth Financing From Lind Partners
August 5, 2024
Ainos Reports Second Quarter 2024 Financial Results
August 4, 2024
Ainos Enrolls First Subject for Clinical Study of VELDONA-Based Animal FCGS Drug
July 22, 2024
Ainos Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA
June 13, 2024
Ainos to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA's Potential Market
May 14, 2024
Ainos Reports First Quarter 2024 Financial Results
May 12, 2024
Ainos Raises $9 Million in Growth Capital with Existing Shareholder
May 6, 2024
Ainos Reports Full Year 2023 Financial Results
March 7, 2024
Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms
February 4, 2024
Ainos Announces $1.75 Million Follow-On Funding
January 23, 2024
Ainos Regains Compliance with Nasdaq Minimum Bid Price Requirement
January 1, 2024
Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-development Powered by AI Nose, Accelerating the Digitalization of Smell
December 25, 2023
Ainos, Inc. Announces Stock Consolidation
December 11, 2023
Ainos Announces Successful Manufacturing of VELDONA GMP Clinical Batch by Swiss Pharmaceutical
November 27, 2023
Ainos Announces Positive Data Reported from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA
November 20, 2023
Ainos Reports Third Quarter 2023 Financial Results
November 8, 2023
Ainos Signs MoU for Contract Clinical Trials to Conduct Clinical Study of Potential New Animal Drug Based on VELDONA
November 5, 2023
Ainos Announces Placement of Initial $3 Million Tranche of $10 Million Private Placement
September 24, 2023
Ainos’ VELDONA Granted Orphan Drug Designation by U.S. FDA for Potential Treatment of Oral Warts in HIV-Seropositive Patients
September 17, 2023
Ainos Commences Shipping its VELDONA Pet Cytoprotein Supplements in Taiwan
September 4, 2023
Ainos Reports Second Quarter 2023 Financial Results
August 10, 2023
Ainos Celebrates First Listing Anniversary on Nasdaq
August 9, 2023
Ainos Completes VELDONA Pet Line-Up by Launching New VELDONA Pet Shiny and Slim in Push Towards $20M Revenue Target
June 13, 2023
Ainos Launches New VELDONA Pet Lohas and Soothing Health Supplements, Catalyzing Its Drive to $20M Sales Target
June 6, 2023
Ainos Launches VELDONA Pet Cytoprotein Health Supplement Targeting $20M in Sales
May 29, 2023